COHERUS ONCOLOGY INCCHRS
ASignal's systematic analysis rates CHRS as Bearish.
Reflects the latest available analysis · analyzed Oct 15, 2026
The case on CHRS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (39.5% YoY)
- High gross margin (68.96%) indicating pricing power
- Cash-rich balance sheet with $105.31M cash vs $54.18M debt
- Debt-to-equity ratio of 0.89x, within moderate range
- Positive financial health and growth scores in fundamentals
- Bearish MACD (MACD < signal line) with negative momentum
- Price below both SMA20 and SMA50, signaling downtrend
- Negative operating and net margins (operating margin: -225.98%)
- Negative ROE (-178.39%) and ROA (-30.52%)
- Negative free cash flow ($-160.15M)
- Low news coverage from a single source (Yahoo)
See the full verdict on CHRS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CHRS
Most investors never get a second opinion, let alone several. ASignal runs CHRS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.